Edasalonexent (CAT-1004) Program

Oral small molecule designed to inhibit NF-κB for the treatment of Duchenne muscular dystrophy

Joanne M. Donovan MD PhD
Chief Medical Officer
Catabasis Pharmaceuticals
November 17, 2018
Forward Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding our expectations and beliefs about our business, future financial and operating performance, clinical trial plans, product development plans and prospects, including statements about future clinical trial plans including, among other things, statements about our single global Phase 3 trial in Duchenne muscular dystrophy, or DMD, to evaluate the efficacy and safety of edasalonexent for registration purposes, and our plans to continue to evaluate data from the open-label extension of our MoveDMD® clinical trial of edasalonexent for the treatment of DMD. The words “believe”, “anticipate”, “plans,” “expect”, “could”, “should”, “will”, “would”, “may”, “intend” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements contained in this presentation and in remarks made during this presentation and the following Q&A session are subject to important risks and uncertainties that may cause actual events or results to differ materially from our current expectations and beliefs, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of our product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products, including our expected target product profile for edasalonexent in DMD; availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of our product candidates; and general economic and market conditions and other factors discussed in the “Risk Factors” section of our Quarterly Report on Form 10-Q for the period ended September 30, 2018, which is on file with the Securities and Exchange Commission, and in other filings that we may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.
Our Mission Is to Bring Hope and Life-Changing Therapies to Patients and Their Families

‣ Our focus is edasalonexent and muscular dystrophy

‣ Our goal is for edasalonexent to preserve muscle function for everyone affected by Duchenne

Catabasis Team
Edasalonexent: Potential to Slow Disease Progression for All Those Affected by Duchenne

- Investigational oral disease-modifying agent for all patients with Duchenne, regardless of mutation type: potential for new standard of care

- Edasalonexent substantially slowed disease progression compared to control

- Potential treatment alone and also exploring potential to combine with dystrophin-targeted therapies
Edasalonexent Inhibits NF-κB, a Key Driver of Disease in Duchenne

↑ Inflammation + Fibrosis

Fibrosis

Inflammation

Cytokines

↓ Regeneration

Satellite Cell

Myoblasts

Myotube

Edasalonexent

Inhibited NF-κB

↓ Degeneration

Slowed Disease Progression
NF-kB Inhibition Provides Potential for Broad Therapeutic Benefit in Muscular Dystrophy

Activated NF-kB leads to disease progression in DMD

- **Skeletal Muscle**
  - Loss of ambulation, upper limb function, respiratory failure

- **Heart**
  - Cardiomyopathy

- **Bone**
  - Fractures

Vision for edasalonexent, an NF-kB inhibitor

- **Improve**
  - skeletal muscle function
- **Improve**
  - cardiac function
- **Reduce**
  - risk of fractures
Promising Clinical Results Seen to Date with Edasalonexent

**NF-κB Target Engagement**
- Inhibition of NF-κB

**Biomarker Improvements**
- Decrease in CRP, biomarker of inflammation
- Decrease in muscle enzymes
- Heart rate decrease to age-normative values

**Muscle MRI Improvements**
- Improvement in rate of change in MRI T2 compared with the rate of change during the off-treatment period
- Decrease in muscle fat accumulation

**Functional Improvements**
- Preservation of function as assessed by North Star Ambulatory Assessment and Timed Function Tests compared with rate of change during off-treatment control period
Edasalonexent Preserved Muscle Function Compared to Off-Treatment Period

**Edasalonexent Treatment Stabilized North Star Ambulatory Assessment Score**

**Edasalonexent Treatment Stabilized Timed Function Tests**

Means ± SEM shown
Edasalonexent Significantly Improved Biomarkers

- Significantly improved CRP and all muscle enzymes, including CK
- Boys affected by Duchenne have elevated heart rates and edasalonexent treatment decreased heart rate towards age-normative values

![Chart showing Heart Rate: Change from Baseline](chart.png)

- Baseline 99 beats/min
- p<0.01
Edasalonexent is well tolerated, with no safety signals or steroid-associated side effects

- No safety signals in 50+ years of patient exposure
- Well tolerated, with majority of adverse events mild in nature
- Boys on edasalonexent grow similar to unaffected boys
  - Favorably differentiated from weight gain and curtailed growth seen with corticosteroid standard of care

Percentiles Compared to CDC Growth Charts

Body Mass Index

Percentiles

0 12 24 36 48 60 72

Weeks on Edasalonexent
Design of Phase 3 PolarisDMD Trial

12-month, randomized, double-blind placebo-controlled trial

| Edasalonexent 100 mg/kg | Placebo |

Open-label extension

| Edasalonexent |

Clinical Trial Site Visits

- **Key enrollment criteria**
  - Age 4 to 7 (up to 8th birthday)
  - Able to complete timed function tests
  - Not on corticosteroids for at least 6 months
  - Not on other investigational therapies for at least 1 month, can be on stable eteplirsen

- **Visits / key assessments every 3 months**
  - North Star Ambulatory Assessment, Timed Function Tests, Muscle Strength
  - Safety measures
  - Assessments of growth, cardiac and bone health
  - No biopsy or 6 minute walk test
Many Clinical Trial Sites in U.S. and Canada to Improve Patient Access

- **Initial sites active and enrolling patients**
- **Additional sites will be active in the coming weeks**
- **Sites also expected in Europe, Australia and Israel**
Our Vision for Edasalonexent:

- For all patients, regardless of mutation, from time of diagnosis throughout their lifetime
- Address both the skeletal and cardiac muscle disease
- Enhance the efficacy of dystrophin targeted therapies
- Favorably differentiated safety and tolerability profile from standard of care

Developing a potential NEW Standard of Care in Duchenne
Learn More and Contact Us with Any Questions

- **Email** our clinical team at DMDtrials@catabasis.com

- **Follow us** on social media for frequent updates @CatabasisPharma

- **Learn more** on our website at [www.catabasis.com](http://www.catabasis.com) and [clinicaltrials.gov](http://clinicaltrials.gov) NCT03703882

- **Sign up** to receive our Newsletter and information updates on our website

And **thank you** PPMD!